Chargement en cours...
Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial
Kyoto University Substance (KUS) 121, an ATPase inhibitor of valosin-containing protein, is a novel neuroprotectant. We tested the safety and effectiveness of KUS121 in patients with acute central retinal artery occlusion (CRAO). We conducted an investigator-initiated, first-in-humans, phase 1/2 cli...
Enregistré dans:
| Publié dans: | PLoS One |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7018138/ https://ncbi.nlm.nih.gov/pubmed/32053676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0229068 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|